Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

New data could revive Pfizer's Mylotarg

This article was originally published in Scrip

Executive Summary

New investigator-initiated research could help revive Pfizer's acute myeloid leukaemia (AML) treatment, Mylotarg (gemtuzumab ozogamicin), following the withdrawal of the product last year.

You may also be interested in...



Pfizer's Mylotarg Likely To Get New Orphan, Biologics Exclusivities

Return to market for leukemia drug expected to generate another orphan drug exclusivity from new indication; Mylotarg also appears on track for 12-year biologics exclusivity after being approved as BLA, rather than an NDA as it was for its initial 2000 approval.

Mylotarg Returns: US FDA Approves Pfizer's Leukemia Drug With Bonus Pediatric Indication

Agency's Oncologic Drugs Advisory Committee had only discussed gemtuzumab as a treatment for adults with acute myeloid leukemia at its July meeting, but labeling includes a pediatric claim based on a 29-patient trial; drug returns to the US market after being withdrawn in 2010 for failure to confirm clinical benefit.

Pfizer's Mylotarg Rejoins AML Market At $24,600 List Price

CD33 inhibiting drug that was yanked from the market in 2010 due to reports of veno-occlusive disease is now fully approved by the US FDA at a lower recommended dose.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

LL1133148

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel